High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation

Damian Mikulski; Mateusz Nowicki; Izabela Dróźdż; Małgorzata Misiewicz; Kacper Piotr Kościelny; Karol Okoński; Kinga Krawiec; Ewelina Perdas; Agnieszka Wierzbowska; Wojciech Fendler

doi:10.3389/fonc.2023.1250355

High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation

Front Oncol. 2023 Sep 27:13:1250355. doi: 10.3389/fonc.2023.1250355. eCollection 2023.

Authors

Affiliations

¹ Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
² Department of Hematooncology, Copernicus Memorial Hospital in Lodz, Lodz, Poland.
³ Department of Hematology and Transplantology, Copernicus Memorial Hospital in Lodz, Lodz, Poland.
⁴ Department of Hematology, Medical University of Lodz, Lodz, Poland.
⁵ Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland.

Abstract

Introduction: AHSCT is the treatment of choice for newly diagnosed patients with transplant-eligible multiple myeloma (MM). However, considerable variability in response to autologous hematopoietic stem cell transplantation (AHSCT) results in only 50% of patients achieving complete response (CR) after AHSCT, which is directly associated with improved progression-free and overall survival (OS). In this study, we aimed to investigate the potential predictive role of selected serum miRNAs in MM patients who underwent AHSCT.

Patients and methods: Serum expression level of 6 miRNAs: miR-221-3p, miR-15b-5p, miR-223-3p, miR-320c, miR-361-3p, and miR-150-5p was evaluated in 51 patients who underwent AHSCT. Blood samples were collected at two time points: before conditioning chemotherapy (T1) and fourteen days after transplant (+14) (T2).

Results: All selected miRNAs significantly changed their expression level across the procedure- two were up-regulated after AHSCT: hsa-miR-320c (FC 1.42, p<0.0001) and hsa-miR-361-3p (FC 1.35, p=0.0168); four were down-regulated: hsa-miR-15b-5p (FC 0.53, p<0.0001), hsa-miR-221-3p (FC 0.78, p=0.0004), hsa-miR-223-3p (FC 0.74, p=0.0015) and hsa-miR-150-5p (FC 0.75, p=0.0080). Notably, before AHSCT, hsa-miR-223-3p was down-regulated in International Staging System (ISS) III patients (FC=0.76, p=0.0155), and hsa-miR-320c was up-regulated (FC=1.27, p=0.0470). These differences became non-significant after AHSCT. Eight (15.69%) patients achieved CR before AHSCT and 17 patients (33.33%) at +100 days after AHSCT. In multivariate logistic regression analysis, achievement of CR after induction and hsa-miR-223-3p at T1 were independent predictors of CR after AHSCT. In multivariate Cox regression analysis, hsa-miR-223-3p at T1 expression level was associated with prolonged OS (HR 0.06, 95%CI: 0.00 - 0.99, p=0.0488).

Conclusion: Serum expression of has-miR-223-3p is a predictor of CR and prolonged OS in MM patients undergoing AHSCT.

Keywords: CR; MiR-223-3p; aHSCT; autologous hematopoietic stem cell transplantation; complete response; miRNA; multiple myeloma.

Grants and funding

The study was funded by the National Science Center grant number 2019/33/B/NZ5/00536 awarded to WF and 2022/45/N/NZ6/02904 awarded to DM.